In BRAF-mutated melanoma, CDK12 activity drives tumor proliferation and genomic stability, while the CDK12/13 inhibitor SR-4835 inhibits DDR gene expression, induces DNA damage, and impairs melanoma growth. Here, BRAF is linked to melanoma.